LOCALIZED SKELETAL EWING’S SARCOMA IN THE REPUBLIC OF BELARUS: LONG-TERM SURVIVAL RATES FOR PEDIATRIC PATIENTS
Abstract
Ewing sarcoma (ES) is the second most common primary bone tumor in children. The aim of this study was to evaluate the clinical outcomes and long-term survival for pediatric patients with localized bone ES. 72 previously untreated patients with localized ES, reported to the sub-cancer registry database from 1999 to 2014, were evaluated. Survival rate was estimated via the Kaplan-Meier method and compared using log-rank tests and Cox proportional hazard models. 15-year overall survival was 64.6 %. Common clinical prognostic factors (age, sex, tumors volume, response to treatment and others) were not different between patients with favorable and unfavorable outcomes.
Treatment results for patients with localized ES from the Republic of Belarus comply with generally accepted standards. Searching for new predictive markers is necessary for early detection of resistant to conventional treatment patients.
Treatment results for patients with localized ES from the Republic of Belarus comply with generally accepted standards. Searching for new predictive markers is necessary for early detection of resistant to conventional treatment patients.
About the Authors
L. P. Kisialeu
Belarusian Research Center for Pediatric Oncology, Hematology and Immunology
Belarus
Belarus
O. V. Aleinikova
Belarusian Research Center for Pediatric Oncology, Hematology and Immunology
Belarus
Belarus
References
1. Aleinikova, O. V., Potapnev, M. P., Sytskevich, O. N., Petrovich, S. V., Ismail-Zade, R. S. and Strongin, Y. S. (2000) “Advances Pediatric Oncology and Hematology in Belarus”, Topical issues of Pediatric Oncology and Hematology: Materials VIII Intern. Symp. Minsk, BY, pp. 3-8.
2. Sukonko, O. G. and Antonenkova, N. A. (2011) “Organizational and methodological assistance provided by the state institution Republican Center of Oncology and Medical Radiology named N. N. Alexandrov for healthcare organizations in the Republic of Belarus”, Onkologicheskii zhurnal [Cancer Journal], no. 20, pp. 42-45.
3. Demidchik, Y. Y., Pisarenko, A. M., Fridman, M. V., Baragina, Z. N., Mankovskaya, S. V. and Papok, V. E. (2011) “Impossible for operation thyroid cancer: effectiveness of diagnosis and survival”, Onkologicheskii zhurnal [Cancer Journal], no. 8, pр. 9-21.
4. Zhavrid, E. A., Antonenkova, N., Prokhorov, V. I. and Lappo, S. V. (2011) “The role of the molecular clock in the pathogenesis and therapy of malignant tumors”, Meditsinskaya panorama [Medical panorama], no. 7, pp. 19-23.
5. Karski, E. E., Matthay, K. K., Neuhaus, J. M., Goldsby, R. E. and Dubois, S. G. (2013) “Characteristics and outcomes of patients with Ewing sarcoma over 40 years of a geat diagnosis”, Cancer Epidemiology, no. 37, pp. 29-33.
6. Cotterill, S. J., Ahrens, S., Paulussen, M., Jürgens, H. F., Voûte, P. A., Gadner, H. and Craft, A. W. (2000) “Prognostic factors in Ewing’s tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing’s Sarcoma Study Group”, Journal of Clinical Oncology, no. 18, pp. 3108-3114.
7. Rodriguez-Galindo, C., Navid, F., Liu T., Billups, C. A., Rao, B. N. and Krasin, M. J. (2008) “Prognostic factors for local and distant control in Ewing sarcoma family of tumors”, Annals of Oncology, no. 19, pp. 814-820.
8. Lee J., Hoang, B. H., Ziogas A. and Zell, J. A. (2010) “Analysis of prognostic factors in Ewing sarcoma using a populationbased cancerregistry”, Cancer, no. 116, pp. 1964-1973.
9. Applebaum, M. A., Worch, J., Matthay, K. K., Goldsby, R., Neuhaus, J., West, D. C. and Dubois, S. G. (2011) “Clinical features and outcomes in patients with extraskeletal Ewing sarcoma”, Cancer, vol. 117 (13), pp. 3027-3032.
10. Petrovich, S., Aleinikova, O. and Shumikhina, T. (2002) “Epidemiological aspects of childhood onco-hematological morbidity in the Republic of Belarus”, Voprosy Onkologii, vol. 48 (3), pp. 301-305.
11. Raney, R. B., Anderson, J. R., Barr, F. G., Donaldson, S. S., Pappo, A. S., Qualman, S. J., Wiener, E. S., Maurer, H. M. and Crist, W. M. (2001) “Rhabdomyosarcoma and undifferentiated sarcoma in the first two decades of life: a selective review of Intergroup Rhabdomyosarcoma Study Group experience and rationale for Intergroup Rhabdomyosarcoma Study V”, Journal of Pediatric Hematology/Oncology, no. 23, pp. 215-220.
12. Paulussen, M., Craft, A.W., Lewis, I., Hackshaw, A., Douglas, C., Dunst, J., Schuck, A., Winkelmann, W., Köhler, G., Poremba, C., Zoubek, A., Ladenstein, R., van den Berg H., Hunold, A., Cassoni, A., Spooner, D., Grimer, R., Whelan, J., McTiernan A. and Jürgens, H. (2008) “Results of the EICESS-92 Study: two randomized trials of Ewing’s sarcoma treatment – cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients”, Journal of Clinical Oncology, no. 26, pp. 4385-4393.
13. Granowetter, L., Womer, R., Devidas, M., Krailo, M., Wang, C., Bernstein, M., Marina, N., Leavey, P., Gebhardt, M., Healey, J., Shamberger, R. C., Goorin, A., Miser, J., Meyer, J., Arndt, C. A., Sailer, S., Marcus, K., Perlman, E., Dickman, P. and Grier, H. E. (2009) “Dose-intensified compared with standard chemotherapy for nonmetastatic Ewing sarcoma family of tumours: a Children’s Oncology Group study”, Journal of Clinical Oncology, no. 27, pp. 2536-2541.
14. Oberlin, O., Rey, A., Desfachelles, A. S., Philip, T., Plantaz, D., Schmitt, C., Plouvier, E., Lejars, O., Rubie, H., Terrier, P. and Michon, J. (2006) “Impact of high-dose busulfan plus melphalan as consolidation in metastatic Ewing tumours: a study by the Societe Francaise des Cancers de l’Enfant”, Journal of Clinical Oncology, no. 24, pp. 3997-4002.
15. Juergens, C., Weston, C., Lewis, I., Whelan, J., Paulussen, M., Oberlin, O., Michon, J., Zoubek, A., Juergens, H. and Craft, A. (2006) “Safety assessment of intensive induction with vincristine, ifosfamide, doxorubicin and etoposide (VIDE) in the treatment of Ewing tumours in the EURO-E.W.I.N.G. 99 clinical trial”, Pediatr Blood Cancer, no. 47, pp. 22-29.
16. Neerav, S., Joshua, D., Schiffman, D. R., Davis, I. J., Womer, R. B., Lessnick, S. L. and Lawlor, E. R. (2013) “Biomarkers in Ewing sarcoma: the promise and challenge of personalized medicine. A report from the Children’s Oncology Group”, Frontiers in oncology, no. 3, pp. 1-13. 14
Review
For citations:
Kisialeu L.P., Aleinikova O.V. LOCALIZED SKELETAL EWING’S SARCOMA IN THE REPUBLIC OF BELARUS: LONG-TERM SURVIVAL RATES FOR PEDIATRIC PATIENTS. Proceedings of the National Academy of Sciences of Belarus, Medical series. 2016;(4):7-14. (In Russ.)
Views: 550
Email this article 